Characteristics of the 48 included articles: definitions of osteoarthritis (OA) and dyslipidemia, outcomes and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) study quality
| Author | OA definition | Dyslipidemia definition | Outcome | STROBE study quality (%) |
| Stürmer et al25 | Arthroplasty or KL≥2 | TC≥240 mg/dL and/or statin therapy | MV in OA+ Association of OA and dyslipidemia | 53 |
| Racaza et al65 | ACR or Cq and Rx | – | NPD in OA+ | 42 |
| Erb et al66 | Cq and Rx | – | MV in OA+ | 50 |
| Eymard et al28 | ACR Cq and Rx KL scale | History of dyslipidemia | NPD in OA+ | 82 |
| Shea et al29 | Cq and Rx | – | NPS in OA+ MV in OA+ | 78 |
| Salamon et al50 | ACR | – | NPD in OA+ MV in OA+ | 72 |
| Abourazzak et al20 | KL≥2 | HDL<50 mg/dL TG≥150 mg/dL | NPD in OA+ | 66 |
| Juge et al17* | Rx | – | NPD in OA+ | NA |
| Rollefstad et al23* | History of OA | – | MV in OA+ and OA– Association of OA and dyslipidemia | NA |
| Saunders et al53* | KL scale | TC>4 mmol/L | NPD in OA+ Association of MV and KL scale | NA |
| Nuñez et al32* | – | Hypercholesterolemia (ND) | NPD in OA+ | NA |
| Shukurova et al67* | - | Hypercholesterolemia (ND) | NPD in OA+ | NA |
| Salaru et al33* | ACR | – | NPD in OA+ | NA |
| Kemta Lekpa et al35* | ACR | – | NPD in OA+ | NA |
| Niu et al36* | Arthroplasty or KL≥2 | HDL<40 mg/dL in M;<50 mg/dL in W TG>150 mg/dL | Association of OA and dyslipidemia | NA |
| Haugen et al43* | KL≥2 | Low HDL and HTG (ND) | NPD in OA+ Association of OA and dyslipidemia | NA |
| Courties et al45* | KL≥2 | – | NPD in OA+ | NA |
| Gandhi et al49 | Cq and Rx | HDL<35 mg/dL in M,<40 mg/dL in W; TG≥150 mg/dL | NPD in OA+ | 52 |
| Laires et al38* | – | – | NPD in OA+ | NA |
| Thelier–Deloison et al15* | History of OA | – | NPD in OA+ and OA– Association of OA and dyslipidemia | NA |
| Soran et al16 | Cq and Rx | – | MV in OA+ and OA– Association of OA and dyslipidemia | 65 |
| Cheras et al18 | Cq and Rx | – | MV in OA+ and OA– Association of OA and dyslipidemia | 75 |
| Mishra et al39 | KL scale ACR | – | MV in OA+ and OA– Association of OA and dyslipidemia | 58 |
| Oliviero et al52 | ACR | – | MV in OA+ and OA– Association OA and dyslipidemia | 67 |
| Addimanda et al47 | Cq KL scale | LDL≥130 mg/dL and/or CT≥240 mg/dL and/or statin therapy | NPD in OA+ and OA– Association of OA and dyslipidemia | 75 |
| Philbin et al55 | Questionnaire Radiological Danielson scale | LDL≥160 mg/dL and/or HDL≤35 mg/dL | NPD in OA+ and OA– NPS in OA+ and OA– Association of OA and dyslipidemia MV in OA+ and OA– | 73 |
| Irshad et al56 | KL scale | TC≥200 mg/dL and/or TG≥150 mg/dL | NPD in OA+ and OA– Association of OA and dyslipidemia MV in OA+ and OA– | 47 |
| Zayed et al40 | ACR | – | MV in OA+ and OA– Association of OA and dyslipidemia | 56 |
| Cheng et al57* | – | – | Association of OA and dyslipidemia | NA |
| Davis et al26 | Rx | – | MV in OA+ and OA– Association of OA and dyslipidemia | 67 |
| Han et al27 | History of OA by physician | HDL<40 mg/dL in M,<50 mg/dL in W; TG≥150 mg/dL | MV in OA+ and OA– Association of OA and dyslipidemia | 84 |
| Dahaghin et al41 | KL≥2, ACR, Cq | – | MV in OA+ and OA– Association of OA and dyslipidemia | 69 |
| Haugen et al42 | KL≥2 | – | NPS in OA+ MV in OA+ | 84 |
| Inoue et al30 | KL≥2 | HDL<40 mg/dL in M,<50 mg/dL in W; TG≥150 mg/dL | NPD in OA+ and OA– Association of OA and dyslipidemia MV in OA+ and OA– | 69 |
| Cemeroglu et al22 | ≥3 articulations with KL≥2 | TC>200 mg/dL LDL>100 mg/dL HDL<40 mg/dL TG>150 mg/dL | NPD in OA+ and OA– MV in OA+ and OA– NPS in OA+ and OA– Association of OA and dyslipidemia | 59 |
| Meek et al51 | Codes | – | MV in OA+ NPS in OA+ | 78 |
| Al-Arfaj31 | KL≥2 | TC≥220 mg/dL | NPD in OA+ and OA– Association of OA and dyslipidemia | 50 |
| Suri et al48 | Pathria and Weishaupt scale | TC≥240 mg/dL | NPD in OA+ and OA– Association of OA and dyslipidemia | 72 |
| Puenpatom et al4 | Codes Rx History of OA by physician | Codes or HDL<40 mg/dL in M,<50 mg/dL in W; or TG≥150 mg/dL | NPD in OA+ and OA– Association of OA and dyslipidemia | 69 |
| Hart et al19 | KL≥2 | – | Association of OA and dyslipidemia | 78 |
| Maddah et al24 | KL≥2 | TC≥5 mmol/L and TG≥2 mmol/L and HDL≤1 mmol/L in M, ≤1.1 mmol/L in W | NPD in OA+ and OA– Association of OA and dyslipidemia MV in OA+ and OA– | 72 |
| Engström et al34 | Codes: arthroplasty for hip or knee OA | HDL<1.03 mmol/L in M,<1.29 mmol/L in W; TG≥1.7 mmol/L or statin therapy | NPD in OA+ and OA– Association of OA and dyslipidemia | 79 |
| Yoshimura et al3 | KL≥2 | HDL≤40 mg/dL | MV in OA+ and OA– Association of OA and dyslipidemia | 91 |
| Nielen et al54 | Codes | Codes: hypercholesterolemia | NPD in OA+ and OA– NPS in OA+ and OA– | 81 |
| Marshall et al44 | KL scale | Codes | NPD in OA+ NPS in OA+ | 74 |
| Hussain et al37 | Joint replacement | HDL<1.03 mmol/L in M,<1.29 mmol/L in W; HTG≥1.7 mmol/L | NPD in OA+ and OA– Association of OA and dyslipidemia | 85 |
| Sowers et al21 | KL≥2 | HDL≤45 mg/dL or LDL>160 mg/dL or TG>200 mg/dL | MV in OA+ and OA– Association of OA and dyslipidemia | 70 |
| Massengale et al46 | – | TC≥240 mg/dL | NPD in OA+ and OA– | 78 |
ACR, American College of Rheumatology; Cq, clinical; HDL, high-density lipoprotein; HTG, hypertriglyceridemia; KL, Kellgren and Lawrence; LDL, low-density lipoprotein; M, men; MV, mean values of lipid profile; NA, if the data were issued only from congress; ND, not defined; NPD, number of patients with dyslipidemia; NPS, number of patients with statin therapy; OA+, patients with osteoarthritis; OA–, patients without osteoarthritis; Rx, radiography; TC, total cholesterol; TG, triglycerides; W, women.
*Data from a congress.